Forecast

Buy	18
Hold	4
Sell	3

News Go to news feed

Novo Nordisk faces mid-term rebound but long-term caution after revenue downgrades

Novo Nordisk is expected to see a short-term stock price recovery following a significant decline and two downward revenue revisions, but analysts urge caution due to reduced growth expectations and lower free cash flow forecasts. The company's valuation appears less attractive despite a lower P/E ratio, as its market cap remains high relative to earnings. Technical analysis suggests a temporary bounce, but further selling pressure may resume in the longer term. » More on investing.com
Novo Nordisk downgraded to 'neutral' by UBS due to uncertain outlook

UBS has downgraded Novo Nordisk from 'buy' to 'neutral' and significantly lowered its price target. The bank sees major challenges ahead for the Danish pharmaceutical company, particularly regarding its weight loss drugs Wegovy and Ozempic. The outlook for the company's cash flow is also considered uncertain. » More on finanzen.net
Novo Nordisk under pressure after renewed profit warning and analyst downgrades

Novo Nordisk is facing major challenges following another profit warning and a downgrade by UBS. Analysts are expressing doubts about the growth prospects of its products Wegovy and Ozempic, while a leadership change is on the horizon. The company must first regain the market's lost trust. » More on deraktionaer.de

Historical dividends Dividends

All dividend metrics All metrics

In 2002, Novo Nordisk 'B' has already paid €0.76 in dividends. The last payout was in March 2002.

Financials

In the last year, Novo Nordisk 'B' had revenue of €232.26B and net profit of €83.68B

(EUR)	2023	YoY
Revenue	232.26B	31.26%
Gross profit	196.5B	32.32%
Net profit	83.68B	50.71%
EBITDA	114.63B	50.01%

Fundamentals

Metric	Value
Market capitalization	€406.69B
Number of shares	4.45B
52-week high/low	€185.12 - €51.65
Dividends	No
Beta	0.24
P/E ratio	11.27
PEG ratio	2.25
P/B ratio	5.91
P/S ratio	3.98

Company profile

Novo Nordisk A/S ist ein Gesundheitsunternehmen, das sich mit der Erforschung, Entwicklung, Herstellung und Vermarktung von pharmazeutischen Produkten befasst. Das Unternehmen ist auch in der Entdeckung, Entwicklung, Herstellung und Vermarktung von pharmazeutischen Produkten tätig. Das Unternehmen ist in zwei Geschäftsbereichen tätig: Diabetes- und Adipositasbehandlung und Biopharmazeutika. Das Segment Diabetes und Adipositas umfasst Insulin, GLP-1, andere proteinbezogene Produkte wie Glucagon, proteinbezogene Verabreichungssysteme und Nadeln sowie orale Antidiabetika. Das Biopharmaziesegment des Unternehmens umfasst die Therapiebereiche Hämophiliebehandlung, Wachstumshormontherapie und Hormonersatztherapie. Das Unternehmen bietet auch das Produkt Saxenda zur Behandlung von Fettleibigkeit an. Das Unternehmen bietet eine Reihe von Produkten an, darunter NovoLog/NovoRapid, NovoLog Mix/NovoMix, Prandin/NovoNorm, NovoSeven, Norditropin und Vagifem. Zum 31. Dezember 2016 vermarktete das Unternehmen seine Produkte in über 180 Ländern. Die regionale Struktur des Unternehmens besteht aus zwei Geschäftseinheiten: Nordamerika und International Operations.

Name	Novo Nordisk 'B'
CEO	Lars Fruergaard Jorgensen
Headquarters	Bagsvaerd, Denmark
Website	novonordisk.com/investors/investor-highlights.html
Sector	Health Care
Industry	Pharmaceuticals
IPO	06/07/2001
Employees	59,337